Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222948 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT02222948 is a Phase 2 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 112 participants.
The verdict
NCT02222948, a Phase 2 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
Primary Objectives: * To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS) patients. * To evaluate multiple doses of vatelizumab for a dose-response. Secondary Objectives: * To evaluate the safety and tolerability of vatelizumab compared to placebo. * To evaluate the pharmacokinetics (PK) of vatelizumab.
Interventions
- DRUG Vatelizumab
- DRUG Placebo (for Vatelizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222948
The ClinicalTrials.gov registry entry for NCT02222948 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vatelizumab is the first listed.
NCT02222948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222948 about?
NCT02222948 is a clinical study titled "Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis". Primary Objectives: * To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS) patients. * To evaluate multiple doses of vatelizumab for a dose-response. Secondary Objectives: * T...
What is the current status of trial NCT02222948?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2014-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02222948?
The interventions under investigation include: Vatelizumab (DRUG), Placebo (for Vatelizumab) (DRUG).
Who is sponsoring clinical trial NCT02222948?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.